|
TGFBR2 KO CAR27/IL-15 NK cells Clinical Trials
3 actively recruiting trials across 1 location
▲ +2 trials since June 2026
Pipeline
Phase 1: 1Phase 1/2: 2
Top Sponsors
- M.D. Anderson Cancer Center3
Indications
- Cancer3
- Lymphoid1
- Myeloid Malignancies1
- Hodgkin Lymphoma1
- Pancreatic Cancer1
Houston, Texas3 trials
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
The University of Texas M. D. Anderson Cancer Center
Phase 1/2
Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer
The University of Texas M. D. Anderson Cancer Center
Phase 1/2
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
The University of Texas M. D. Anderson Cancer Center
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.